NASDAQ · MRNA
Moderna, Inc.
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
Loading market information…
OTC · VXRT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vaxart, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vaxart, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.070.0% vs estimate |
| $20.88M+632.49% vs estimate |
| Q4 2024 | Mar 20, 2025 | -$0.05+50.0% vs estimate | $15.19M-26.88% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.06+40.0% vs estimate | $4.93M-68.55% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$222.76+$8.60 (+4.01%)
Moderna, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.46% below the high.
$62.61+$1.15 (+1.87%)
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
DKK 247.80-DKK 7.80 (-3.05%)
Bavarian Nordic A/S’s quoted price sits in the upper half of its reported 52-week range, 3.58% below the high.
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$10.47+$0.15 (+1.45%)
Novavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.81% below the high.
€2.56-€0.00 (-0.08%)
Valneva SE’s quoted price sits in the lower half of its reported 52-week range, 50.33% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
